A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06440005 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Advanced Cancer
Locally Advanced Carcinoma
Metastatic Solid Tumor
Breast Cancer
Prostate Cancer
Colorectal Cancer
Pancreatic Cancer
Liver Cancer
Angiosarcoma
Solid Tumor

Interventions

DRUG: AGX101

Sponsor

Angiex, Inc.